What Rhythm Metabolic does

Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the development and commercialization of precision medicines for rare neuroendocrine diseases. Its therapeutic platform targets the melanocortin-4 receptor (MC4R) pathway to treat hyperphagia (pathological, insatiable hunger) and severe obesity caused by rare genetic variants or hypothalamic injury, including Bardet-Biedl syndrome, POMC/PCSK1/LEPR deficiency obesities, acquired hypothalamic obesity, and Prader-Willi syndrome. The company's lead product is IMCIVREE (setmelanotide), a first-in-class MC4R agonist injection approved by the FDA in 2020 for POMC and LEPR deficiency obesity, expanded to BBS in 2022, and authorized by the European Commission; a further label expansion was approved in 2026.

The commercial product is paired with a deep late-stage pipeline that diversifies modality and frequency of administration: Bivamelagon (LB54640), an oral, non-hyperpigmenting MC4R-specific agonist acquired from LG Chem Life Sciences in 2024 (Phase 2 SIGNAL trial in acquired hypothalamic obesity); and RM-718, a weekly MC4R-specific agonist also designed to avoid hyperpigmentation, in Phase 2. Underpinning this pipeline is a proprietary DNA sequencing data platform containing approximately 80,000 de-identified genetic samples from individuals with severe obesity, used in genetic epidemiological analyses to identify rare MC4R pathway variants.

Rhythm operates as a commercial rare disease biopharma with field sales and patient support infrastructure. IMCIVREE is distributed through specialty pharmacy channels and HUB services (including the Rhythm InTune patient support program), reimbursed via payer/negotiated pathways for confirmed genetic diagnoses. The company generates essentially all revenue from pharmaceutical product sales (IMCIVREE) in the US and Europe, operates a wholly-owned Dutch subsidiary and a UK subsidiary for European commercialization, and is publicly traded on Nasdaq (ticker RYTM) since a 2017 IPO with cumulative financing exceeding $1 billion led by CFO Hunter Smith. The company employs 400+ staff across North America and Europe and is headquartered at 222 Berkeley Street, Boston, Massachusetts.

Name

Rhythm Metabolic

Legal name

Rhythm Pharmaceuticals, Inc.

Website

https://rhythmtx.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company developing precision MC4R pathway medicines (lead: IMCIVREE/setmelanotide) for rare neuroendocrine diseases including Bardet-Biedl syndrome and POMC/PCSK1/LEPR deficiency obesity, supported by an injectable, oral and weekly pipeline.

Ownership category

akta.pro rank

Product category

Rare Disease Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

akta.pro secondary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Rare disease therapeutics
• Precision medicine development
• MC4R receptor agonists
• Genetic obesity treatments
• Orphan drug therapy

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical product sales (IMCIVREE): Rhythm generates revenue through the commercial sale of its FDA-approved drug IMCIVREE (setmelanotide) injection, prescribed to patients with rare MC4R pathway obesity conditions. Revenue is derived from prescription volumes in the US and Europe following regulatory approvals.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and sells precision medicines for rare neuroendocrine diseases. Its core commercial product is IMCIVREE (setmelanotide), an FDA-approved MC4R receptor agonist injection for chronic weight management in patients with monogenic or syndromic obesity due to POMC, PCSK1, or LEPR deficiency and Bardet-Biedl syndrome. The company also advances a pipeline of oral and weekly MC4R agonists (Bivamelagon, RM-718) and operates a proprietary DNA sequencing data platform supporting rare obesity research.

Product overview

Rhythm Pharmaceuticals is a global biopharmaceutical company with a focused portfolio of precision medicines for rare neuroendocrine diseases. The core product is IMCIVREE (setmelanotide), an FDA-approved injection for chronic weight management in patients with rare obesity caused by MC4R pathway impairments. The pipeline includes Bivamelagon (LB54640), an oral MC4R agonist in Phase 2 for acquired hypothalamic obesity, and RM-718, a weekly MC4R agonist also in Phase 2. Supporting offerings include Rhythm InTune patient support program and a proprietary DNA sequencing data platform of approximately 80,000 genetic samples for research.

Differentiator

Problem solved

Functional benefit

Brands

• IMCIVREE: FDA-approved setmelanotide injection for rare obesity conditions
• Rhythm InTune
• LEAD for Rare Obesity
• GOLD Academy
• Uncovering Rare Obesity

Products and services

• IMCIVREE (setmelanotide) injection FDA-approved MC4R agonist precision medicine injection for chronic weight management in patients 6 years and older with monogenic or syndromic obesity due to POMC, PCSK1, or LEPR deficiency, or Bardet-Biedl syndrome (BBS). Prescribed by endocrinologists, geneticists, and obesity specialists and dispensed via specialty pharmacy channels.
• Bivamelagon (LB54640) Investigational oral, MC4R-specific agonist designed not to cause hyperpigmentation. Being evaluated in Phase 2 as a potential therapy for acquired hypothalamic obesity, intended to broaden treatment options beyond injectable setmelanotide.
• RM-718 Investigational weekly MC4R-specific agonist designed not to cause hyperpigmentation, currently in Phase 2 development for rare MC4R pathway obesity indications.

Quantifiable outcome

• Phase 3 TRANSCEND trial completed for congenital hypothalamic obesity; Phase 3 EMANATE ongoing for POMC/LEPR insufficiency and SRC1/SH2B1 deficiency obesity.
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• LG Chem Life SciencescoreOEM/ Whitelabel/ Licensing Partner · 1 January 2024In 2024, Rhythm acquired the oral MC4R agonist LB54640 (now called Bivamelagon) from LG Chem Life Sciences. This acquisition expanded Rhythm's pipeline with an investigational oral therapy that does not cause hyperpigmentation, complementing the existing setmelanotide franchise.
• XinventocoreStrategic or Co-development Partner · 1 January 2023Rhythm acquired Xinvento in 2023, expanding its pipeline and capabilities in rare neuroendocrine diseases. The acquisition contributed to Rhythm's ongoing expansion of treatment options for patients with rare MC4R pathway diseases.
• Physician-scientist community / Investigator-initiated research partnersminorStrategic or Co-development PartnerRhythm supports investigator-initiated studies focused on neuroendocrine diseases including natural history, genotype-phenotype correlations, energy expenditure, hyperphagia, and real-world experience with setmelanotide. Studies are scoped to rare MC4R pathway diseases; general obesity or non-rare disease studies are outside scope.

Scale indicators5 records

Recent moves11 records

Expansion highlights8 records

Direct peers

• Soleno Therapeutics: Soleno Therapeutics is developing DCCR (diazoxide choline) for Prader-Willi syndrome, directly overlapping Rhythm's PWS Phase 2 setmelanotide program and competing for the same hyperphagia/obesity patient population. It is the most direct clinical competitor in Rhythm's franchise expansion path.
• Crinetics Pharmaceuticals: Crinetics focuses on rare endocrine diseases with an oral peptide platform (e.g., paltusotine for acromegaly). Direct overlap with Rhythm's rare-neuroendocrine / MC4R scientific area, plus shared business model of developing precision medicines for small endocrine patient populations.

Emerging players

• Aardvark Therapeutics: Aardvark is developing oral small molecules (e.g., ARD-101) targeting hunger and metabolic signaling pathways, including rare genetic obesity indications. Directly comparable in mechanism-goal (modulating hunger/weight) and rare-disease positioning.
• Krystal Biotech: Krystal Biotech is a commercial-stage rare-disease biotech with approved Vyjuvek, distributed through specialty channels. Head of North America Jennifer Lee came from Krystal; the company shares the small-team, focused-portfolio, rare-disease launch playbook Rhythm employs.
• Viking Therapeutics: Viking Therapeutics is a clinical-stage biotech focused on obesity and metabolic disease with an oral and injectable pipeline. Comparable in therapeutic area and stage-gated development model; represents emerging competition in metabolic disease that could overlap with Rhythm's next-gen obesity ambitions.

Broad incumbents

• BioMarin Pharmaceutical: BioMarin is a large rare-disease commercial biopharma operating globally with multiple approved enzyme replacement and gene therapy products. Comparable in rare-disease commercialization model, regulatory expertise, and patient-finding infrastructure underpinning Rhythm's specialty-pharmacy/HUB go-to-market.
• Ultragenyx Pharmaceutical: Ultragenyx commercializes multiple rare-disease enzyme replacement and gene therapy products globally. Shares Rhythm's model of identifying tiny patient populations for inherited metabolic disorders and operating specialty distribution plus field sales infrastructure.
• Alexion (AstraZeneca Rare Disease): Alexion pioneered ultra-rare-disease specialty pharma with Soliris/Strensiq and was an explicit career background of multiple Rhythm executives (and Chief Regulatory Officer Alicia Fiscus). Benchmark for the rare-disease commercial model Rhythm follows.
• Eli Lilly: Lilly leads the broader obesity space with Zepbound (tirzepatide) and an extensive obesity pipeline including MC4R-pathway-adjacent programs. The dominant commercial threat and benchmark for obesity therapeutic economics that Rhythm's next-gen pipeline (oral Bivamelagon, weekly RM-718) seeks to compete with on tolerability/dosing.
• Novo Nordisk: Novo Nordisk sets the standard in obesity therapeutics with Wegovy/Saxenda and an expanding pipeline (CagriSema). Directly comparable in disease area (obesity) but operates at vastly larger scale in common obesity; defines the reimbursement and competitive backdrop against which Rhythm's rare-genetic franchise must justify pricing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/RhythmPharma
• LinkedInlinkedin.com/company/rhythm-pharmaceuticals-inc-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rhythm Metabolic